Owen W J Prall
Overview
Explore the profile of Owen W J Prall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
1392
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ng J, Cai L, Girard L, Prall O, Rajan N, Khoo C, et al.
Clin Cancer Res
. 2024 Jan;
30(9):1846-1858.
PMID: 38180245
Purpose: The classification of small cell lung cancer (SCLC) into distinct molecular subtypes defined by ASCL1, NEUROD1, POU2F3, or YAP1 (SCLC-A, -N, -P, or -Y) expression, paves the way for...
2.
Posner A, Sivakumaran T, Pattison A, Etemadmoghadam D, Thio N, Wood C, et al.
J Immunother Cancer
. 2023 Jan;
11(1).
PMID: 36720497
Background: Cancer of unknown primary (CUP) is a heterogeneous group of metastatic cancers where a primary tissue of origin (TOO) is uncertain. Most patients with CUP have limited treatment options...
3.
Cabalag C, Prall O, Ciciulla J, Galea L, Thio N, Jayawardana M, et al.
Ann Surg Oncol
. 2022 Oct;
30(3):1614-1625.
PMID: 36183015
Background: In esophageal cancer (EC), there is a paucity of knowledge regarding the interplay between the tumor immune microenvironment and response to neoadjuvant treatment and, therefore, which factors may influence...
4.
McEvoy C, Kee D, Prall O, Clay T, Scott C, Backhouse A, et al.
JCO Precis Oncol
. 2022 Feb;
3:1-2.
PMID: 35100731
No abstract available.
5.
Wang R, Solomon B, Luen S, Prall O, Khoo C, Gill A, et al.
Endocrinol Diabetes Metab Case Rep
. 2022 Jan;
2022.
PMID: 35023475
Summary: Adrenocortical carcinoma is a rare disease with poor prognosis whose clinical heterogeneity can at times present a challenge to accurate and timely diagnosis. We present the case of a...
6.
Lucas C, Gupta R, Wu J, Shah K, Ravindranathan A, Barreto J, et al.
Acta Neuropathol
. 2021 Nov;
143(1):109-113.
PMID: 34825267
No abstract available.
7.
Prall O, Browning J, Nastevski V, Caporarello S, Bates B, Hewitt C, et al.
Pathology
. 2021 Oct;
54(3):279-285.
PMID: 34635319
Therapeutically actionable ROS1 rearrangements have been described in 1-3% of non-small cell lung cancer (NSCLC). Screening for ROS1 rearrangements is recommended to be by immunohistochemistry (IHC), followed by confirmation with...
8.
9.
Prall O, Thio N, Yerneni S, Kumar B, McEvoy C
Pathology
. 2021 Jan;
53(5):663-666.
PMID: 33454140
No abstract available.
10.
McEvoy C, Holliday H, Thio N, Mitchell C, Choong D, Yellapu B, et al.
Lab Invest
. 2020 Sep;
101(1):26-37.
PMID: 32873880
Most NUTM1-rearranged neoplasms (NRNs) have fusions between NUTM1 and BRD (bromodomain-containing) family members and are termed NUT carcinomas (NCs) because they show some squamous differentiation. However, some NRNs are associated...